Responder analyses for anti-amyloid immunotherapies for Alzheimer's disease: a paradigm shift by regulatory authorities is urgently needed.
作者信息
Salemme Simone, Ancidoni Antonio, Vanacore Nicola
机构信息
Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena 41125, Italy.
National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome 00161, Italy.
出版信息
Brain Commun. 2023 Oct 24;5(5):fcad276. doi: 10.1093/braincomms/fcad276. eCollection 2023.
Abstract
摘要
相似文献
1
Responder analyses for anti-amyloid immunotherapies for Alzheimer's disease: a paradigm shift by regulatory authorities is urgently needed.阿尔茨海默病抗淀粉样蛋白免疫疗法的应答者分析：监管机构亟需进行范式转变。
Brain Commun. 2023 Oct 24;5(5):fcad276. doi: 10.1093/braincomms/fcad276. eCollection 2023.
2
High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.阿尔茨海默病中的高清除率抗淀粉样蛋白免疫疗法。第1部分：疗效和安全性数据的荟萃分析与综述以及医学经济学方面
Rev Neurol (Paris). 2022 Dec;178(10):1011-1030. doi: 10.1016/j.neurol.2022.06.012. Epub 2022 Sep 29.
3
Photo-oxygenation by a biocompatible catalyst reduces amyloid-β levels in Alzheimer's disease mice.光氧作用通过生物相容的催化剂降低阿尔茨海默病小鼠中的淀粉样-β水平。
Brain. 2021 Jul 28;144(6):1884-1897. doi: 10.1093/brain/awab058.
4
Restoring regulatory T-cell dysfunction in Alzheimer's disease through expansion.通过扩增恢复阿尔茨海默病中调节性T细胞功能障碍。
Brain Commun. 2020 Jul 20;2(2):fcaa112. doi: 10.1093/braincomms/fcaa112. eCollection 2020.
5
High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France.阿尔茨海默病中的高清除率抗淀粉样蛋白免疫疗法。第2部分：获批后的假定情况和时间线、法国的使用建议、实施及伦理考量
Rev Neurol (Paris). 2022 Dec;178(10):999-1010. doi: 10.1016/j.neurol.2022.08.002. Epub 2022 Nov 3.
6
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?针对阿尔茨海默病的淀粉样蛋白免疫疗法还有希望吗？
Curr Opin Psychiatry. 2014 Mar;27(2):128-37. doi: 10.1097/YCO.0000000000000041.
7
Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.改变阿尔茨海默病的进程：即将出现的抗淀粉样蛋白疾病修正疗法。
Prim Care Companion J Clin Psychiatry. 2007;9(1):32-41. doi: 10.4088/pcc.v09n0106.
8
Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.社论：阿尔茨海默病的疾病修饰治疗靶点，包括淀粉样 β 和tau 蛋白。
Med Sci Monit. 2021 Jul 26;27:e934077. doi: 10.12659/MSM.934077.
9
Alzheimer's drug-development pipeline: 2016.2016年阿尔茨海默病药物研发进展
Alzheimers Dement (N Y). 2016 Aug 17;2(4):222-232. doi: 10.1016/j.trci.2016.07.001. eCollection 2016 Nov.
10
Alzheimer's Disease Prevention and Treatment: Case for Optimism.阿尔茨海默病的预防与治疗：乐观的理由
Ann Integr Mol Med. 2020;2(1):115-130. doi: 10.33597/aimm.02-1008.
引用本文的文献
1
The Profile of the Italian Centers for Cognitive Disorders and Dementia in the Context of New Drugs in Alzheimer's Disease.意大利认知障碍和痴呆中心在阿尔茨海默病新药背景下的概况。
J Alzheimers Dis. 2024;101(2):509-524. doi: 10.3233/JAD-240594.
本文引用的文献
1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
2
Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease.评估用于阿尔茨海默病的抗淀粉样蛋白免疫疗法的关键问题。
Brain Commun. 2023 Jun 2;5(3):fcad175. doi: 10.1093/braincomms/fcad175. eCollection 2023.
3
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
4
Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.临床前和前驱认知阶段认知结局的临床相关变化：对临床阿尔茨海默病试验的影响。
Neurology. 2022 Sep 13;99(11):e1142-e1153. doi: 10.1212/WNL.0000000000200817. Epub 2022 Jul 14.
5
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.两项早期阿尔茨海默病中阿杜卡努单抗的随机 3 期研究。
J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30.
6
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.评估食品和药物管理局和欧洲药品管理局批准的系统肿瘤治疗药物以及对生活质量有临床意义的改善：系统评价。
JAMA Netw Open. 2021 Feb 1;4(2):e2033004. doi: 10.1001/jamanetworkopen.2020.33004.
7
Embedded Pragmatic Trials in Dementia Care: Realizing the Vision of the NIA IMPACT Collaboratory.痴呆症护理中的嵌入式实用临床试验：实现 NIA IMPACT 协作研究的愿景。
J Am Geriatr Soc. 2020 Jul;68 Suppl 2(Suppl 2):S1-S7. doi: 10.1111/jgs.16621.
8
Vitamin E and donepezil for the treatment of mild cognitive impairment.维生素E与多奈哌齐治疗轻度认知障碍
N Engl J Med. 2005 Jun 9;352(23):2379-88. doi: 10.1056/NEJMoa050151. Epub 2005 Apr 13.
9
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.565例阿尔茨海默病患者的长期多奈哌齐治疗（AD2000）：随机双盲试验。
Lancet. 2004 Jun 26;363(9427):2105-15. doi: 10.1016/S0140-6736(04)16499-4.
Zotero 插件